J&J: positive results in plaque psoriasis

(CercleFinance.com) - Johnson & Johnson today announced new data for icotrokinra (JNJ-2113) in plaque psoriasis (PsO), demonstrating the superiority of this oral tablet over the injectable biologic ustekinumab.


Data from the ICONIC-LEADa phase 3 study, presented as a late-breaking abstract at the American Academy of Dermatology (AAD) 2025 annual meeting, show that daily intake of icotrokinra demonstrated significant skin clearance and a favorable safety profile in adults and adolescents aged 12 and over with moderate-to-severe plaque psoriasis.

At week 24, almost half of icotrokinra-treated patients achieved completely clear skin, while similar proportions of patients experienced adverse events (AEs) between the icotrokinra (49%) and placebo (49%) groups, with no new safety signals identified.

These study results are promising and show the potential of icotrokinra treatment to offer patients the unique combination of completely clear skin and a favorable safety profile in a once-daily tablet, the study investigator said.

Johnson & Johnson will now launch a Phase 3 study to demonstrate the superiority of icotrokinra over an injectable biologic, ustekinumab, which would represent 'an important advance in psoriasis research'.

The strong results seen to date underscore icotrokinra's potential to change expectations for the treatment of moderate-to-severe plaque psoriasis, Johnson & Johnson said.


Copyright (c) 2025 CercleFinance.com. All rights reserved.